{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:05Z","timestamp":1793060045500,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["Grant number: ISRM\/12(06)\/2019 ID 2018-2807"],"award-info":[{"award-number":["Grant number: ISRM\/12(06)\/2019 ID 2018-2807"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00705-023-05770-1","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:03:09Z","timestamp":1682679789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus"],"prefix":"10.1007","volume":"168","author":[{"given":"Neha","family":"Bhise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Akshay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-2268","authenticated-orcid":false,"given":"Kavita","family":"Lole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"5770_CR1","unstructured":"WHO Factsheet Hepatitis E [Internet]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-e"},{"issue":"2","key":"5770_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3851\/IMP2705","volume":"19","author":"Z Abbas","year":"2014","unstructured":"Abbas Z, Afzal R (2014) Hepatitis E: when to treat and how to treat. Antivir Ther 19(2):125\u2013131. https:\/\/doi.org\/10.3851\/IMP2705","journal-title":"Antivir Ther"},{"issue":"10","key":"5770_CR3","doi-asserted-by":"publisher","first-page":"25711","DOI":"10.3390\/ijms161025711","volume":"16","author":"D Lapa","year":"2015","unstructured":"Lapa D, Capobianchi MR, Garbuglia AR (2015) Epidemiology of hepatitis E virus in European countries. Int J Mol Sci 16(10):25711\u201325743. https:\/\/doi.org\/10.3390\/ijms161025711","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5770_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/jmv.24336","volume":"88","author":"AM Passos-Castilho","year":"2016","unstructured":"Passos-Castilho AM, de Sena A, Geraldo A, Spada C, Granato CF (2016) High prevalence of hepatitis E virus antibodies among blood donors in Southern Brazil. J Med Virol 88(2):361\u2013364. https:\/\/doi.org\/10.1002\/jmv.24336","journal-title":"J Med Virol"},{"issue":"1","key":"5770_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40011-011-0004-y","volume":"82","author":"VA Arankalle","year":"2012","unstructured":"Arankalle VA (2012) Hepatitis e in India. Proc Natl Acad Sci Sect B Biol Sci 82(1):43\u201353. https:\/\/doi.org\/10.1007\/s40011-011-0004-y","journal-title":"Proc Natl Acad Sci Sect B Biol Sci"},{"issue":"2","key":"5770_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/0970-0218.66864","volume":"35","author":"NT Chauhan","year":"2010","unstructured":"Chauhan NT, Prajapati P, Trivedi AV, Bhagyalaxmi A (2010) Epidemic investigation of the jaundice outbreak in Girdharnagar, Ahmedabad, Gujarat, India, 2008. Indian J Commun Med 35(2):294\u2013297. https:\/\/doi.org\/10.4103\/0970-0218.66864","journal-title":"Indian J Commun Med"},{"issue":"1","key":"5770_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1080\/21505594.2021.1922027","volume":"12","author":"MA El-Mokhtar","year":"2021","unstructured":"El-Mokhtar MA, Karam-Allah Ramadan H, Abdel Hameed MR, Kamel AM, Mandour SA, Ali M, Abdel-Malek MAY, Abd El-Kareem DM, Adel S, Salama EH, Khalaf KAB, Sayed IM (2021) Evaluation of hepatitis E antigen kinetics and its diagnostic utility for prediction of the outcomes of hepatitis E virus genotype 1 infection. Virulence 12(1):1334\u20131344. https:\/\/doi.org\/10.1080\/21505594.2021.1922027","journal-title":"Virulence"},{"key":"5770_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/IDR.S289766","volume":"14","author":"IM Sayed","year":"2021","unstructured":"Sayed IM, El-Mokhtar MA, Mahmoud MAR, Elkhawaga AA, Gaber S, Seddek NH, Abdel-Wahid L, Ashmawy AM, Alkareemy EAR (2021) Clinical outcomes and prevalence of hepatitis e virus (Hev) among non-a-c hepatitis patients in Egypt. Infect Drug Resist 14:59\u201369. https:\/\/doi.org\/10.2147\/IDR.S289766","journal-title":"Infect Drug Resist"},{"issue":"2","key":"5770_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/0002-9343[81]90758-0","volume":"70","author":"MS Khuroo","year":"1981","unstructured":"Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI (1981) Incidence and severity of viral hepatitis in pregnancy. Am J Med 70(2):252\u2013255. https:\/\/doi.org\/10.1016\/0002-9343[81]90758-0","journal-title":"Am J Med"},{"key":"5770_CR10","doi-asserted-by":"publisher","unstructured":"Patra S, Kumar A, Shubha D, Trivedi S, Puri M, Sarin SK (2007) Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. www.annals.org. https:\/\/doi.org\/10.7326\/0003-4819-147-1-200707030-00005","DOI":"10.7326\/0003-4819-147-1-200707030-00005"},{"issue":"11","key":"5770_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/CSHPERSPECT.A032144","volume":"8","author":"HR Dalton","year":"2018","unstructured":"Dalton HR, Izopet J (2018) Transmission and epidemiology of hepatitis e virus genotype 3 and 4 infections. Cold Spring Harb Perspect Med 8(11):1\u201320. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A032144","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"13","key":"5770_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/nejmra1204512","volume":"367","author":"JH Hoofnagle","year":"2012","unstructured":"Hoofnagle JH, Nelson KE, Purcell RH (2012) Hepatitis E. N Engl J Med 367(13):1237\u20131244. https:\/\/doi.org\/10.1056\/nejmra1204512","journal-title":"N Engl J Med"},{"issue":"1","key":"5770_CR13","doi-asserted-by":"publisher","first-page":"e15618","DOI":"10.5812\/hepatmon.15618","volume":"14","author":"Y Geng","year":"2014","unstructured":"Geng Y, Zhang H, Huang W, Harrison TJ, Geng K, Li Z, Wang Y (2014) Persistent hepatitis E virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon 14(1):e15618. https:\/\/doi.org\/10.5812\/hepatmon.15618","journal-title":"Hepat Mon"},{"key":"5770_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcv.2015.10.011","volume":"73","author":"T Lachish","year":"2015","unstructured":"Lachish T, Erez O, Daudi N, Shouval D, Schwartz E (2015) Acute hepatitis E virus in pregnant women in Israel and in other industrialized countries. J Clin Virol 73:20\u201324. https:\/\/doi.org\/10.1016\/j.jcv.2015.10.011","journal-title":"J Clin Virol"},{"issue":"4","key":"5770_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/liv.13557","volume":"38","author":"M Fraga","year":"2018","unstructured":"Fraga M, Doerig C, Moulin H, Bihl F, Brunner F, M\u00fcllhaupt B, Ripellino P, Semela D, Stickel F, Terziroli Beretta-Piccoli B, Aubert V, Telenti A, Greub G, Sahli R, Moradpour D (2018) Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. Liver Int 38(4):619\u2013626. https:\/\/doi.org\/10.1111\/liv.13557","journal-title":"Liver Int"},{"issue":"9","key":"5770_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/omcr\/omy059","volume":"2018","author":"AEM Robins","year":"2018","unstructured":"Robins AEM, Bowden DJ, Gelson WTH (2018) Chronic genotype 1 hepatitis e infection from immunosuppression for ileo-colonic Crohn\u2019s disease. Oxf Med Case Reports 2018(9):278\u2013281. https:\/\/doi.org\/10.1093\/omcr\/omy059","journal-title":"Oxf Med Case Reports"},{"issue":"3","key":"5770_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jceh.2020.07.006","volume":"11","author":"S Rathi","year":"2021","unstructured":"Rathi S, Duseja A, Thakur V, Ratho RK, Singh MP, Taneja S, Das A, Aggarwal R, Dhiman RK, Chawla YK (2021) Chronic hepatitis E with genotype 1\u2014masquerading as allograft rejection after liver transplantation. J Clin Exp Hepatol 11(3):400\u2013403. https:\/\/doi.org\/10.1016\/j.jceh.2020.07.006","journal-title":"J Clin Exp Hepatol"},{"issue":"8","key":"5770_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/nejmoa0706992","volume":"358","author":"N Kamar","year":"2008","unstructured":"Kamar N, Selves J, Mansuy J-M, Ouezzani L, P\u00e9ron J-M, Guitard J, Cointault O, Esposito L, Abravanel F, Danjoux M, Durand D, Vinel J-P, Izopet J, Rostaing L (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358(8):811\u2013817. https:\/\/doi.org\/10.1056\/nejmoa0706992","journal-title":"N Engl J Med"},{"issue":"3","key":"5770_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jhep.2007.12.008","volume":"48","author":"RH Purcell","year":"2008","unstructured":"Purcell RH, Emerson SU (2008) Hepatitis E: an emerging awareness of an old disease. J Hepatol 48(3):494\u2013503. https:\/\/doi.org\/10.1016\/j.jhep.2007.12.008","journal-title":"J Hepatol"},{"issue":"3","key":"5770_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/rmv.522","volume":"17","author":"SK Panda","year":"2007","unstructured":"Panda SK, Thakral D, Rehman S (2007) Hepatitis E virus. Rev Med Virol 17(3):151\u2013180. https:\/\/doi.org\/10.1002\/rmv.522","journal-title":"Rev Med Virol"},{"issue":"1","key":"5770_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0042-6822[91]90760-9","volume":"185","author":"AW Tam","year":"1991","unstructured":"Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, Reyes GR (1991) Hepatitis E virus [HEV]: molecular cloning and sequencing of the full-length viral genome. Virology 185(1):120\u2013131. https:\/\/doi.org\/10.1016\/0042-6822[91]90760-9","journal-title":"Virology"},{"issue":"8","key":"5770_CR22","first-page":"484","volume":"13","author":"LB Murrison","year":"2017","unstructured":"Murrison LB, Sherman KE (2017) The enigma of hepatitis E virus. Gastroenterology and Hepatology 13(8):484\u2013491 (PMID: 28867980)","journal-title":"Gastroenterology and Hepatology"},{"issue":"12","key":"5770_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1007471","volume":"14","author":"J Gouttenoire","year":"2018","unstructured":"Gouttenoire J, Poll\u00e1n A, Abrami L, Oechslin N, Mauron J, Matter M, Oppliger J, Szkolnicka D, Dao Thi VL, van der Goot FG, Moradpour D (2018) Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion. PLoS Pathog 14(12):1\u201324. https:\/\/doi.org\/10.1371\/journal.ppat.1007471","journal-title":"PLoS Pathog"},{"issue":"4","key":"5770_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1005521","volume":"12","author":"VP Nair","year":"2016","unstructured":"Nair VP, Anang S, Subramani C, Madhvi A, Bakshi K, Srivastava A, Shalimar, Nayak B, Ranjith Kumar CT, Surjit M (2016) Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus. PLoS Pathog 12(4):1\u201331. https:\/\/doi.org\/10.1371\/journal.ppat.1005521","journal-title":"PLoS Pathog"},{"issue":"6","key":"5770_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/fpd.2020.2896","volume":"18","author":"G Ferri","year":"2021","unstructured":"Ferri G, Vergara A (2021) Hepatitis E virus in the food of animal origin: a review. Foodborne Pathog Dis 18(6):368\u2013377. https:\/\/doi.org\/10.1089\/fpd.2020.2896","journal-title":"Foodborne Pathog Dis"},{"issue":"10","key":"5770_CR26","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijerph10104507","volume":"10","author":"DM Yugo","year":"2013","unstructured":"Yugo DM, Meng XJ (2013) Hepatitis E virus: foodborne, waterborne and zoonotic transmission. Int J Environ Res Public Health 10(10):4507\u20134533. https:\/\/doi.org\/10.3390\/ijerph10104507","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"5770_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/v8090253","volume":"8","author":"MS Khuroo","year":"2016","unstructured":"Khuroo MS, Khuroo MS, Khuroo NS (2016) Transmission of hepatitis E virus in developing countries. Viruses 8(9):253. https:\/\/doi.org\/10.3390\/v8090253","journal-title":"Viruses"},{"issue":"11","key":"5770_CR28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3390\/pathogens11111337","volume":"11","author":"IM Sayed","year":"2022","unstructured":"Sayed IM, Abdelwahab SF (2022) Is hepatitis E virus a neglected or emerging pathogen in Egypt? Pathogens 11(11):1337. https:\/\/doi.org\/10.3390\/pathogens11111337","journal-title":"Pathogens"},{"issue":"3","key":"5770_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/TP.0b013e3181c4096c","volume":"89","author":"N Kamar","year":"2010","unstructured":"Kamar N, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssi\u00e8re L, Cointault O, Ribes D, Cardeau I, Nogier MB, Mansuy JM, Muscari F, Peron JM, Izopet J, Rostaing L (2010) Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 89(3):353\u2013360. https:\/\/doi.org\/10.1097\/TP.0b013e3181c4096c","journal-title":"Transplantation"},{"issue":"5","key":"5770_CR30","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","volume":"140","author":"N Kamar","year":"2011","unstructured":"Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassutoviguier E, Thervet E, Conti F, Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C, Radenne S, Roqueafonso AM, Rostaing L (2011) Factors associated with chronic hepatitis in patients with hepatitis e virus infection who have received solid organ transplants. Gastroenterology 140(5):1481\u20131489. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.050","journal-title":"Gastroenterology"},{"issue":"5","key":"5770_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2014.08.040","volume":"147","author":"Y Debing","year":"2014","unstructured":"Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B, Manns M, Wedemeyer H, Suneetha PV, Neyts J (2014) A mutation in the hepatitis e virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 147(5):1008-1011.e7. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.040","journal-title":"Gastroenterology"},{"issue":"3","key":"5770_CR32","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1128\/AAC.02496-15","volume":"60","author":"S Lhomme","year":"2016","unstructured":"Lhomme S, Kamar N, Nicot F, Ducos J, Bismuth M, Garrigue V, Petitjean-Lecherbonnier J, Ollivier I, Alessandri-Gradt E, Goria O, Barth H, Perrin P, Saune K, Dubois M, Carcenac R, Lefebvre C, Jeanne N, Abravanel F, Izopet J (2016) Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy. Antimicrob Agents Chemother 60(3):1608\u20131614. https:\/\/doi.org\/10.1128\/AAC.02496-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5770_CR33","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.27990","volume":"62","author":"IM Sayed","year":"2015","unstructured":"Sayed IM, Vercouter AS, Abdelwahab SF, Vercauteren K, Meuleman P (2015) Is hepatitis E virus an emerging problem in industrialized countries? Hepatology 62(6):1883\u20131892. https:\/\/doi.org\/10.1002\/hep.27990","journal-title":"Hepatology"},{"issue":"10","key":"5770_CR34","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","volume":"65","author":"D Todt","year":"2016","unstructured":"Todt D, Gisa A, Radonic A, Nitsche A, Behrendt P, Suneetha PV, Pischke S, Bremer B, Brown RJP, Manns MP, Cornberg M, Thomas Bock C, Steinmann E, Wedemeyer H (2016) In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 65(10):1733\u20131743. https:\/\/doi.org\/10.1136\/gutjnl-2015-311000","journal-title":"Gut"},{"issue":"1","key":"5770_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-020-01343-9","volume":"17","author":"C Wu","year":"2020","unstructured":"Wu C, Wu X, Xia J (2020) Hepatitis e virus infection during pregnancy. Virol J 17(1):1\u201311. https:\/\/doi.org\/10.1186\/s12985-020-01343-9","journal-title":"Virol J"},{"issue":"1","key":"5770_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","volume":"150","author":"VL Dao Thi","year":"2016","unstructured":"Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, Gouttenoire J (2016) Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 150(1):82-85.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.09.011","journal-title":"Gastroenterology"},{"key":"5770_CR37","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.93193","author":"M Rudrapal","year":"2020","unstructured":"Rudrapal M, Khairnar SJ, Jadhav AG (2020) Drug repurposing (DR): an\u00a0emerging approach in drug discovery. Drug Repurposing Hypothesis Mol Aspects Ther Appl. https:\/\/doi.org\/10.5772\/intechopen.93193","journal-title":"Drug Repurposing Hypothesis Mol Aspects Ther Appl"},{"issue":"1","key":"5770_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40203-021-00093-y","volume":"9","author":"BR Tietcheu Galani","year":"2021","unstructured":"Tietcheu Galani BR, Ayissi Owona VB, Guemmogne Temdie RJ, Metzger K, Atsama Amougou M, Djamen Chuisseu PD, Fondjo Kouam A, Ngounoue Djuidje M, Aliouat-Denis C-M, Cocquerel L, Fewou Moundipa P (2021) In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus. In Silico Pharmacol 9(1):1\u201317. https:\/\/doi.org\/10.1007\/s40203-021-00093-y","journal-title":"In Silico Pharmacol"},{"issue":"11","key":"5770_CR39","first-page":"976","volume":"112","author":"Y Tu","year":"1999","unstructured":"Tu Y (1999) The development of new antimalarial drugs: qinghaosu and dihydro-qinghaosu. Chin Med J [Engl] 112(11):976\u2013977 (PMID: 11721477)","journal-title":"Chin Med J [Engl]"},{"issue":"1","key":"5770_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157488606775252584","volume":"1","author":"F Nosten","year":"2008","unstructured":"Nosten F, McGready R, d\u2019Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa T, Brabin B (2008) Antimalarial drugs in pregnancy: a review. Curr Drug Saf 1(1):1\u201315. https:\/\/doi.org\/10.2174\/157488606775252584","journal-title":"Curr Drug Saf"},{"key":"5770_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijid.2019.08.030","volume":"89","author":"YI Kouakou","year":"2019","unstructured":"Kouakou YI, Tod M, Leboucher G, Lavoignat A, Bonnot G, Bienvenu AL, Picot S (2019) Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria. Int J Infect Dis 89:30\u201344. https:\/\/doi.org\/10.1016\/j.ijid.2019.08.030","journal-title":"Int J Infect Dis"},{"issue":"2","key":"5770_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/mol.64.2.382","volume":"64","author":"T Efferth","year":"2003","unstructured":"Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64(2):382\u2013394. https:\/\/doi.org\/10.1124\/mol.64.2.382","journal-title":"Mol Pharmacol"},{"issue":"2","key":"5770_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3851\/imp1467","volume":"8","author":"J Utzinger","year":"2007","unstructured":"Utzinger J, Xiao SH, Tanner M, Keiser J (2007) Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8(2):105\u2013116. https:\/\/doi.org\/10.3851\/imp1467","journal-title":"Curr Opin Investig Drugs"},{"issue":"8","key":"5770_CR44","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3851\/IMP1467","volume":"14","author":"G Siakallis","year":"2009","unstructured":"Siakallis G, Spandidos DA, Sourvinos G (2009) Herpesviridae and novel inhibitors. Antivir Ther 14(8):1051\u20131064. https:\/\/doi.org\/10.3851\/IMP1467","journal-title":"Antivir Ther"},{"issue":"October 2018","key":"5770_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","volume":"163","author":"RF Chemaly","year":"2019","unstructured":"Chemaly RF, Hill JA, Voigt S, Peggs KS (2019) In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review. Antiviral Res 163(October 2018):50\u201358. https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.008","journal-title":"Antiviral Res"},{"issue":"4","key":"5770_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00109-001-0300-8","volume":"80","author":"T Efferth","year":"2002","unstructured":"Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES (2002) Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med 80(4):233\u2013242. https:\/\/doi.org\/10.1007\/s00109-001-0300-8","journal-title":"J Mol Med"},{"issue":"1","key":"5770_CR47","first-page":"66","volume":"76","author":"L Zamidei","year":"2010","unstructured":"Zamidei L, Durval A, Bettocchi D, Luzzio MG, Bartoloni A, Consales G (2010) Efficacy and safety of quinine-artesunate in an HIV-positive patient with severe falciparum malaria. Minerva Anestesiol 76(1):66\u201369 (Epub 2009 Oct 7. PMID: 20125075)","journal-title":"Minerva Anestesiol"},{"issue":"1","key":"5770_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/aps.2008.5","volume":"30","author":"C Wohlfarth","year":"2009","unstructured":"Wohlfarth C, Efferth T (2009) Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin 30(1):25\u201330. https:\/\/doi.org\/10.1038\/aps.2008.5","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"5770_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2005.07.005","volume":"68","author":"MR Romero","year":"2005","unstructured":"Romero MR, Efferth T, Serrano MA, Casta\u00f1o B, MacIas RIR, Briz O, Marin JJG (2005) Effect of artemisinin\/artesunate as inhibitors of hepatitis B virus production in an \u201cin vitro\u201d replicative system. Antiviral Res 68(2):75\u201383. https:\/\/doi.org\/10.1016\/j.antiviral.2005.07.005","journal-title":"Antiviral Res"},{"key":"5770_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-015-1285-7","author":"R Dai","year":"2016","unstructured":"Dai R, Xiao X, Peng F, Li M, Gong G (2016) Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication. Virus Genes. https:\/\/doi.org\/10.1007\/s11262-015-1285-7","journal-title":"Virus Genes"},{"issue":"26","key":"5770_CR51","doi-asserted-by":"publisher","first-page":"15270","DOI":"10.1073\/pnas.251555098","volume":"98","author":"SU Emerson","year":"2001","unstructured":"Emerson SU, Zhang M, Meng XJ, Nguyen H, St Claire M, Govindarajan S, Huang YK, Purcell RH (2001) Recombinant hepatitis E virus genomes infectious for primates: Importance of capping and discovery of a cis-reactive element. Proc Natl Acad Sci USA 98(26):15270\u201315275. https:\/\/doi.org\/10.1073\/pnas.251555098","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"5770_CR52","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1128\/jvi.00146-12","volume":"86","author":"P Shukla","year":"2012","unstructured":"Shukla P, Nguyen HT, Faulk K, Mather K, Torian U, Engle RE, Emerson SU (2012) Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol 86(10):5697\u20135707. https:\/\/doi.org\/10.1128\/jvi.00146-12","journal-title":"J Virol"},{"issue":"24","key":"5770_CR53","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1128\/jvi.01475-10","volume":"84","author":"D Cao","year":"2010","unstructured":"Cao D, Huang Y-W, Meng X-J (2010) The nucleotides on the stem-loop RNA structure in the junction region of the hepatitis E virus genome are critical for virus replication. J Virol 84(24):13040\u201313044. https:\/\/doi.org\/10.1128\/jvi.01475-10","journal-title":"J Virol"},{"issue":"5","key":"5770_CR54","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jhep.2006.05.019","volume":"45","author":"D Sun","year":"2006","unstructured":"Sun D, Nassal M (2006) Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 45(5):636\u2013645. https:\/\/doi.org\/10.1016\/j.jhep.2006.05.019","journal-title":"J Hepatol"},{"issue":"21","key":"5770_CR55","doi-asserted-by":"publisher","first-page":"e00754","DOI":"10.1128\/jvi.00754-17","volume":"91","author":"N Kaushik","year":"2017","unstructured":"Kaushik N, Subramani C, Anang S, Muthumohan R, Shalimar, Nayak B, Ranjith-Kumar CT, Surjit M (2017) Zinc salts block hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase. J Virol 91(21):e00754-e817. https:\/\/doi.org\/10.1128\/jvi.00754-17","journal-title":"J Virol"},{"key":"5770_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/srep26827","author":"PB Devhare","year":"2016","unstructured":"Devhare PB, Desai S, Lole KS (2016) Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies OPEN. Nat Publ Group. https:\/\/doi.org\/10.1038\/srep26827","journal-title":"Nat Publ Group"},{"issue":"7","key":"5770_CR57","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1128\/JVI.02130-09","volume":"84","author":"YA Karpe","year":"2010","unstructured":"Karpe YA, Lole KS (2010) NTPase and 5\u2019 to 3\u2019 RNA duplex-unwinding activities of the hepatitis E virus helicase domain. J Virol 84(7):3595\u20133602. https:\/\/doi.org\/10.1128\/JVI.02130-09","journal-title":"J Virol"},{"issue":"1","key":"5770_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.virusres.2013.11.022","volume":"179","author":"V Mhaindarkar","year":"2014","unstructured":"Mhaindarkar V, Sharma K, Lole KS (2014) Mutagenesis of hepatitis E virus helicase motifs: effects on enzyme activity. Virus Res 179(1):26\u201333. https:\/\/doi.org\/10.1016\/j.virusres.2013.11.022","journal-title":"Virus Res"},{"issue":"9","key":"5770_CR59","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1099\/jgv.0.000528","volume":"97","author":"S Mahilkar","year":"2016","unstructured":"Mahilkar S, Paingankar MS, Lole KS (2016) Hepatitis E virus RNA-dependent RNA polymerase: RNA template specificities, recruitment and synthesis. J Gen Virol 97(9):2231\u20132242. https:\/\/doi.org\/10.1099\/jgv.0.000528","journal-title":"J Gen Virol"},{"issue":"1","key":"5770_CR60","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jhep.2016.02.045","volume":"65","author":"Y Debing","year":"2016","unstructured":"Debing Y, Moradpour D, Neyts J, Gouttenoire J (2016) Update on hepatitis e virology: implications for clinical practice. J Hepatol 65(1):200\u2013212. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.045","journal-title":"J Hepatol"},{"issue":"6","key":"5770_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v11060485","volume":"11","author":"V Kinast","year":"2019","unstructured":"Kinast V, Burkard TL, Todt D, Steinmann E (2019) Hepatitis E virus drug development. Viruses 11(6):1\u201316. https:\/\/doi.org\/10.3390\/v11060485","journal-title":"Viruses"},{"issue":"10","key":"5770_CR62","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1056\/nejmc0903778","volume":"361","author":"HR Dalton","year":"2009","unstructured":"Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S (2009) Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 361(10):1025\u20131027. https:\/\/doi.org\/10.1056\/nejmc0903778","journal-title":"N Engl J Med"},{"issue":"8","key":"5770_CR63","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/ndt\/gfq282","volume":"25","author":"N Kamar","year":"2010","unstructured":"Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, Izopet J, Rostaing L (2010) Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant 25(8):2792\u20132795. https:\/\/doi.org\/10.1093\/ndt\/gfq282","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"5770_CR64","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jhep.2016.11.016","volume":"66","author":"S Pischke","year":"2017","unstructured":"Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA (2017) Hepatitis E virus: infection beyond the liver? J Hepatol 66(5):1082\u20131095. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.016","journal-title":"J Hepatol"},{"issue":"12","key":"5770_CR65","doi-asserted-by":"publisher","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","volume":"123","author":"AM Di Bisceglie","year":"1995","unstructured":"Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH (1995) Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123(12):897\u2013903. https:\/\/doi.org\/10.7326\/0003-4819-123-12-199512150-00001","journal-title":"Ann Intern Med"},{"key":"5770_CR66","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3201\/eid2412.180937","volume":"24","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, Yip CCY, Wu S, Cai J, Zhang JX, Leung KH, Chung TWH, Chan FW, Chan WM, Teng JLL et al (2018) Rat hepatitis E virus as cause of persistent hepatitis after liver transplant. Emerg Infect Dis 24:2241\u20132250. https:\/\/doi.org\/10.3201\/eid2412.180937","journal-title":"Emerg Infect Dis"},{"key":"5770_CR67","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/infdis\/jiz025","volume":"220","author":"A Andonov","year":"2019","unstructured":"Andonov A, Robbins M, Borlang J, Cao J, Hatchette T, Stueck A, Deschambault Y, Murnaghan K, Varga J, Johnston L (2019) Rat hepatitis E virus linked to severe acute hepatitis in an immunocompetent patient. J Infect Dis 220:951\u2013955. https:\/\/doi.org\/10.1093\/infdis\/jiz025","journal-title":"J Infect Dis"},{"issue":"10","key":"5770_CR68","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/cb500512z","volume":"9","author":"S Mukherjee","year":"2014","unstructured":"Mukherjee S, Weiner WS, Schroeder CE, Simpson DS, Hanson AM, Sweeney NL, Marvin RK, Ndjomou J, Kolli R, Isailovic D, Schoenen FJ, Frick DN (2014) Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem Biol 9(10):2393\u20132403. https:\/\/doi.org\/10.1021\/cb500512z","journal-title":"ACS Chem Biol"},{"issue":"6","key":"5770_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.20517\/2394-5079.2018.25","volume":"4","author":"M Irshad","year":"2018","unstructured":"Irshad M, Gupta P, Irshad K (2018) Molecular targeting of antiviral drugs used against hepatitis C virus infection. Hepatoma Res 4(6):23. https:\/\/doi.org\/10.20517\/2394-5079.2018.25","journal-title":"Hepatoma Res"},{"issue":"3","key":"5770_CR70","doi-asserted-by":"publisher","first-page":"310","DOI":"10.14218\/JCTH.2018.00005","volume":"6","author":"S Anang","year":"2018","unstructured":"Anang S, Kaushik N, Surjit M (2018) Recent advances towards the development of a potent antiviral against the hepatitis E virus. J Clin Transl Hepatol 6(3):310\u2013316. https:\/\/doi.org\/10.14218\/JCTH.2018.00005","journal-title":"J Clin Transl Hepatol"},{"issue":"9","key":"5770_CR71","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s12272-017-0949-3","volume":"40","author":"G Jin","year":"2017","unstructured":"Jin G, Lee J, Lee K (2017) Chemical genetics-based development of small molecules targeting hepatitis C virus. Arch Pharmacal Res 40(9):1021\u20131036. https:\/\/doi.org\/10.1007\/s12272-017-0949-3","journal-title":"Arch Pharmacal Res"},{"key":"5770_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5753804","author":"MK Parvez","year":"2018","unstructured":"Parvez MK, Subbarao N (2018) Molecular analysis and modeling of hepatitis E virus helicase and identification of novel inhibitors by virtual screening. Biomed Res Int. https:\/\/doi.org\/10.1155\/2018\/5753804","journal-title":"Biomed Res Int"},{"issue":"4","key":"5770_CR73","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4103\/bbrj.bbrj_149_20","volume":"4","author":"R Satpathy","year":"2020","unstructured":"Satpathy R (2020) In Silico modeling and docking study of potential helicase (nonstructural proteins) inhibitors of novel coronavirus 2019 (severe acute respiratory syndrome coronavirus 2). Biomed Biotechnol Res J 4(4):330\u2013336. https:\/\/doi.org\/10.4103\/bbrj.bbrj_149_20","journal-title":"Biomed Biotechnol Res J"},{"key":"5770_CR74","doi-asserted-by":"publisher","unstructured":"Khater S, Das G (2020). Repurposing Ivermectin to inhibit the activity of SARS CoV2 helicase: possible implications for COVID 19 therapeutics. https:\/\/doi.org\/10.31219\/osf.io\/8dseq","DOI":"10.31219\/osf.io\/8dseq"},{"key":"5770_CR75","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12084822","author":"M Balasubramaniam","year":"2020","unstructured":"Balasubramaniam M, Reis RJS (2020) Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins. ChemRxiv The Preprint Server for Chemistry. https:\/\/doi.org\/10.26434\/chemrxiv.12084822","journal-title":"ChemRxiv The Preprint Server for Chemistry"},{"issue":"3","key":"5770_CR76","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12250-020-00242-1","volume":"35","author":"T Shu","year":"2020","unstructured":"Shu T, Huang M, Wu D, Ren Y, Zhang X, Han Y, Mu J, Wang R, Qiu Y, Zhang DY, Zhou X (2020) SARS-coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virologica Sinica 35(3):321\u2013329. https:\/\/doi.org\/10.1007\/s12250-020-00242-1","journal-title":"Virologica Sinica"},{"issue":"4","key":"5770_CR77","doi-asserted-by":"publisher","first-page":"336","DOI":"10.14218\/JCTH.2016.00038","volume":"4","author":"N Gamal","year":"2016","unstructured":"Gamal N, Gitto S, Andreone P (2016) Efficacy and safety of daclatasvir in hepatitis C: an overview. J Clin Transl Hepatol 4(4):336\u2013344. https:\/\/doi.org\/10.14218\/JCTH.2016.00038","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"5770_CR78","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.gastro.2016.05.060","volume":"152","author":"MC Donnelly","year":"2017","unstructured":"Donnelly MC, Imlach SN, Abravanel F, Ramalingam S, Johannessen I, Petrik J, Fraser AR, Campbell JD, Bramley P, Dalton HR, Hayes PC, Kamar N, Simpson KJ (2017) Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV\/HCV co-infected liver transplant recipient. Gastroenterology 152(1):300\u2013301. https:\/\/doi.org\/10.1053\/j.gastro.2016.05.060","journal-title":"Gastroenterology"},{"issue":"10","key":"5770_CR79","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00705-017-3444-8","volume":"162","author":"C Qu","year":"2017","unstructured":"Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W (2017) Nucleoside analogue 2\u2019-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. Adv Virol 162(10):2989\u20132996. https:\/\/doi.org\/10.1007\/s00705-017-3444-8","journal-title":"Adv Virol"},{"issue":"7","key":"5770_CR80","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1053\/j.gastro.2014.02.036","volume":"146","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJW, Neyts J, Janssen HLA, Metselaar HJ, Peppelenbosch MP, Pan Q (2014) Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis e virus. Gastroenterology 146(7):1775\u20131783. https:\/\/doi.org\/10.1053\/j.gastro.2014.02.036","journal-title":"Gastroenterology"},{"key":"5770_CR81","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00003-19","author":"NE Netzler","year":"2019","unstructured":"Netzler NE, Tuipulotu DE, Vasudevan SG, Mackenzie JM, White PA (2019) Antiviral candidates for treating hepatitis E virus infection. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00003-19","journal-title":"Antimicrob Agents Chemother"},{"key":"5770_CR82","unstructured":"Drug Central 2021: Online drug Compendium [https:\/\/drugcentral.org\/drugcard\/247]"},{"key":"5770_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2210-1-12","volume":"1","author":"PL Olliaro","year":"2001","unstructured":"Olliaro PL, Nair NK, Sathasivam K, Mansor SM, Navaratnam V (2001) Pharmacokinetics of artesunate after single oral administration to rats. BMC Pharmacol 1:1\u20134. https:\/\/doi.org\/10.1186\/1471-2210-1-12","journal-title":"BMC Pharmacol"},{"issue":"37","key":"5770_CR84","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.2174\/138161212803582397","volume":"18","author":"T Qidwai","year":"2012","unstructured":"Qidwai T, Yadav DK, Khan F, Dhawan S, Bhakuni RS (2012) QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum. Curr Pharm Des 18(37):6133\u20136154. https:\/\/doi.org\/10.2174\/138161212803582397","journal-title":"Curr Pharm Des"},{"issue":"1","key":"5770_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1475-2875-10-49","volume":"10","author":"MA Onyamboko","year":"2011","unstructured":"Onyamboko MA, Meshnick SR, Fleckenstein L, Koch MA, Atibu J, Lokomba V, Douoguih M, Hemingway-Foday J, Wesche D, Ryder RW, Bose C, Wright LL, Tshefu AK, Capparelli EV (2011) Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC. Malar J 10(1):49. https:\/\/doi.org\/10.1186\/1475-2875-10-49","journal-title":"Malar J"},{"key":"5770_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10:1\u201317. https:\/\/doi.org\/10.1186\/1475-2875-10-263","journal-title":"Malar J"},{"issue":"4","key":"5770_CR87","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2165\/00003495-199550040-00009","volume":"50","author":"LB Barradell","year":"1995","unstructured":"Barradell LB, Fitton A (1995) Artesunate: a review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs 50(4):714\u2013741. https:\/\/doi.org\/10.2165\/00003495-199550040-00009","journal-title":"Drugs"},{"issue":"2","key":"5770_CR88","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1046\/j.1365-2125.1998.00655.x","volume":"45","author":"KT Batty","year":"1998","unstructured":"Batty KT, Thu LTA, Davis TME, Ilett KF, Mai TX, Hung NC, Tien NP, Powell SM, Thien HV, Binh TQ, Kim NV (1998) A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br J Clin Pharmacol 45(2):123\u2013129. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00655.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"5770_CR89","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/AAC.44.4.972-977.2000","volume":"44","author":"P Newton","year":"2000","unstructured":"Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N (2000) Antimalarial bioavailability and disposition of artesunate in acute falciparum, malaria. Antimicrob Agents Chemother 44(4):972\u2013977. https:\/\/doi.org\/10.1128\/AAC.44.4.972-977.2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5770_CR90","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1086\/591195","volume":"47","author":"T Efferth","year":"2008","unstructured":"Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJG, Marschall M (2008) The antiviral activities of artemisinin and artesunate. Clin Infect Dis 47(6):804\u2013811. https:\/\/doi.org\/10.1086\/591195","journal-title":"Clin Infect Dis"},{"issue":"March","key":"5770_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.649532","volume":"12","author":"FM Uckun","year":"2021","unstructured":"Uckun FM, Saund S, Windlass H, Trieu V (2021) Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug. Front Pharmacol 12(March):1\u20135. https:\/\/doi.org\/10.3389\/fphar.2021.649532","journal-title":"Front Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s00705-023-05799-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000}}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-023-05770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-023-05770-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-023-05770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:53:01Z","timestamp":1744213981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-023-05770-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5770"],"URL":"https:\/\/doi.org\/10.1007\/s00705-023-05770-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00705-023-05799-2","asserted-by":"object"}]},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"16 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00705-023-05799-2","URL":"https:\/\/doi.org\/10.1007\/s00705-023-05799-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"147"}}